CBS004, a Novel Monoclonal Antibody Against Bdca-2 Inhibits TLR-Induced Activation of Human pDC in Vitro and In Vivo. a Novel Therapeutic Target for Systemic Sclerosis

Corinaldesi, C, El-Sherbiny, YM, Migneco, G et al. (4 more authors) (2018) CBS004, a Novel Monoclonal Antibody Against Bdca-2 Inhibits TLR-Induced Activation of Human pDC in Vitro and In Vivo. a Novel Therapeutic Target for Systemic Sclerosis. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL. Wiley .

Metadata

Authors/Creators:
Keywords: Dendritic cells; interferons; monoclonal antibodies; mouse model and systemic sclerosis
Dates:
  • Published: 1 September 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Infection and Immunity (Leeds)
The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Clinical Musculoskeletal Medicine (LIRMM) (Leeds)
Funding Information:
FunderGrant number
Capella Bioscience LtdNOEXT REF GIVEN
Depositing User: Symplectic Publications
Date Deposited: 25 Jun 2019 14:01
Last Modified: 25 Jun 2019 14:01
Status: Published
Publisher: Wiley
Identification Number: https://doi.org/10.1002/art.40700
Related URLs:

Share / Export

Statistics